MedTrace Logo

Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast)

NCT02032043 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 14457

Last updated 2018-05-04

No results posted yet for this study

Summary

Approximately 4,000 people will participate per year. The study population will include females and males over 5 years of age who live in filariasis and onchocerciasis endemic areas. Subject selection will not be based on health status.

Two sites will be studied, and each study will last for 4 years. Participants will be studied only once in cross-sectional surveys. Some subjects may be included in more than one annual population survey, but this is not a longitudinal study.

Investigators will compare annual and semiannual mass drug administration (MDA) for lymphatic filariasis and onchocerciasis, and investigators will compare the impact of these MDA schedules on soil transmitted helminth infections. MDA will be administered by others (Ivorian Ministry of Health).

The investigators will test the hypothesis that semiannual mass drug administration (MDA) is superior to annual MDA for elimination of lymphatic filariasis, onchocerciasis and for control of soil transmitted helminth (STH) infections.

1. Compare the relative impact and cost effectiveness of annual vs. twice yearly mass drug administration (MDA) for elimination of lymphatic filariasis (LF) in these populations.
2. Compare the relative impact and cost effectiveness of annual vs. twice yearly mass drug administration (MDA) for elimination of onchocerciasis in these populations.
3. Study the impact of annual vs. semiannual MDA on soil transmitted helminth (STH) infection in these populations.

Conditions

  • Lymphatic Filariasis
  • Onchocerciasis
  • Soil Transmitted Helminth (STH) Infections

Interventions

DRUG

Annual versus Semiannual Albendazole plus Ivermectin MDA

Annual or semiannual Albendazole plus Ivermectin, administered by the Ivorian Ministry of Health.

Sponsors & Collaborators

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Gary J Weil, MD · Washington University School of Medicine

  • Peter U Fischer, PhD · Washington University School of Medicine

  • Aboulaye Miete, MD · Ivory Coast Ministry of Health, National Program Against Filariasis, Schistosomiasis and Geohelminths

Eligibility

Min Age
5 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2017-12-04
Completion
2017-12-04

Countries

  • Côte d’Ivoire

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02032043 on ClinicalTrials.gov